George A. Eldridge - 18 Nov 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Issuer symbol
JBIO
Transactions as of
18 Nov 2022
Net transactions value
-$17,932
Form type
4
Filing time
22 Nov 2022, 19:00:11 UTC
Previous filing
16 Dec 2021
Next filing
28 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $1,843 +861 +44% $2.14* 2,821 18 Nov 2022 Direct F1, F2
transaction AVTE Common Stock Sale $15,174 -780 -28% $19.45 2,041 18 Nov 2022 Direct F1, F3
transaction AVTE Common Stock Sale $1,631 -81 -4% $20.13 1,960 18 Nov 2022 Direct F1, F4
transaction AVTE Common Stock Options Exercise $4.28 +2 +0.1% $2.14* 1,962 21 Nov 2022 Direct F1
transaction AVTE Common Stock Sale $38 -2 -0.1% $19.00 1,960 21 Nov 2022 Direct F1
transaction AVTE Common Stock Options Exercise $372 +174 +8.9% $2.14* 2,134 22 Nov 2022 Direct F1
transaction AVTE Common Stock Sale $3,308 -174 -8.2% $19.01 1,960 22 Nov 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -861 -0.87% $0.000000 97,815 18 Nov 2022 Common Stock 861 $2.14 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -2 -0% $0.000000 97,813 21 Nov 2022 Common Stock 2 $2.14 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -174 -0.18% $0.000000 97,639 22 Nov 2022 Common Stock 174 $2.14 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
F2 Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.06 to $20.045, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.095 to $20.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.03, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer